VIR BIOTECHNOLOGY, INC.

(VIR)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
All news about VIR BIOTECHNOLOGY, INC.
05/12HC Wainwright Adjusts Vir Biotechnology Price Target to $125 From $200, Maintains Buy R..
MT
05/11Pfizer's $11.6 billion Biohaven buy could spark more biotech deals
RE
05/05Earnings Flash (VIR) VIR BIOTECHNOLOGY Reports Q1 Revenue $1.23B, vs. Street Est of $81..
MT
05/05VIR BIOTECHNOLOGY, INC. Management's Discussion and Analysis of Financial Condition an..
AQ
05/05Earnings Flash (VIR) VIR BIOTECHNOLOGY Reports Q1 Revenue $1.23B, vs. Street Est of $81..
MT
05/05Vir Biotechnology Provides Corporate Update and Reports First Quarter 2022 Financial Re..
GL
05/05Vir Biotechnology Provides Corporate Update and Reports First Quarter 2022 Financial Re..
AQ
05/05Vir Biotechnology, Inc. Reports Earnings Results for the First Quarter Ended March 31, ..
CI
05/02INSIDER SELL : Vir Biotechnology
MT
04/27TRANSCRIPT : Vir Biotechnology, Inc. - Special Call
CI
04/27Vir Biotechnology Announces New Data From the MARCH Hepatitis B Trial, Unveils New Hepa..
GL
04/27Vir Biotechnology Announces New Data From the MARCH Hepatitis B Trial, Unveils New Hepa..
GL
04/27GSK tops forecasts as consumer health spin-off nears
RE
04/23SHAREHOLDER ALERT : Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vir B..
PR
04/21Vir Biotechnology to Provide Corporate Update and Report First Quarter 2022 Financial R..
GL
04/13Vir Biotechnology to Host a Virtual Hepatitis Portfolio R&D Day
AQ
04/11SHAREHOLDER ALERT : Pomerantz Law Firm Investigates Claims On Behalf of Investors Vir Biot..
PR
04/08Vir Biotechnology Appoints Johanna Friedl-Naderer as COO
MT
04/07VIR BIOTECHNOLOGY, INC. : Change in Directors or Principal Officers, Financial Statements ..
AQ
04/07Vir Biotechnology, Inc. Appoints Johanna Friedl-Naderer as Executive Vice President and..
CI
04/06Vir Biotechnology Scientists Named Winners of the BARDA and HHS-Sponsored Pediatric COV..
GL
04/05Vir Biotechnology Says FDA Exclusion Applied to Sotrovimab in March Now Extended to 'Al..
MT
04/05VIR BIOTECHNOLOGY, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
04/05Vir Biotechnology, Inc. Announces FDA's Exclusion Has Been Extended to All U.S. Regions
CI
04/05FDA pulls authorization for GSK-Vir's COVID therapy as BA.2 cases rise
RE
04/04Vir Biotechnology to Participate in the 21st Annual Needham Healthcare Conference
AQ
04/04VIR BIOTECHNOLOGY, INC.(NASDAQGS : VIR) added to S&P Composite 1500
CI
04/04VIR BIOTECHNOLOGY, INC.(NASDAQGS : VIR) added to S&P 600
CI
04/04VIR BIOTECHNOLOGY, INC.(NASDAQGS : VIR) added to S&P 600 Health Care
CI
04/04VIR BIOTECHNOLOGY, INC.(NASDAQGS : VIR) added to S&P 1000
CI
04/01VIR BIOTECHNOLOGY, INC.(NASDAQGS : VIR) added to S&P Composite 1500
CI
04/01VIR BIOTECHNOLOGY, INC.(NASDAQGS : VIR) added to S&P 600
CI
04/01VIR BIOTECHNOLOGY, INC.(NASDAQGS : VIR) added to S&P 600 Health Care
CI
03/31VIR BIOTECHNOLOGY, INC.(NASDAQGS : VIR) added to S&P 600
CI
03/31VIR BIOTECHNOLOGY, INC.(NASDAQGS : VIR) added to S&P Composite 1500
CI
03/31VIR BIOTECHNOLOGY, INC.(NASDAQGS : VIR) added to S&P 600 Health Care
CI
03/30SECTOR UPDATE : Health Care Stocks Close Slightly Lower
MT
03/30SECTOR UPDATE : Health Care Stocks Still Trying to Find Direction
MT
03/30Top Midday Gainers
MT
03/30Vir Biotechnology Shares Rise Amid Joining S&P SmallCap 600 Next Month
MT
03/30WALL STREET STOCK EXCHANGE : Should you buy on the cannons?
03/30HC Wainwright Adjusts Vir Biotechnology's Price Target to $200 From $300, Reiterates Bu..
MT
03/30VIR BIOTECHNOLOGY, INC.(NASDAQGS : VIR) added to S&P 600
CI
03/30VIR BIOTECHNOLOGY, INC.(NASDAQGS : VIR) added to S&P 600 Health Care
CI
03/30VIR BIOTECHNOLOGY, INC.(NASDAQGS : VIR) added to S&P Composite 1500
CI
03/29Camden Property to Join S&P 500; Matador to Join MidCap 400; Vir Biotech to Join SmallC..
MT
03/29VIR BIOTECHNOLOGY, INC.(NASDAQGS : VIR) added to S&P 600
CI
03/29VIR BIOTECHNOLOGY, INC.(NASDAQGS : VIR) added to S&P 600 Health Care
CI
03/29VIR BIOTECHNOLOGY, INC.(NASDAQGS : VIR) added to S&P Composite 1500
CI
03/28Needham Adjusts Vir Biotechnology's Price Target to $45 from $80, Keeps Buy Rating
MT
03/27US FDA Limits Use of GSK's COVID-19 Antibody to Certain Regions Amid Omicron Subvariant
MT
03/25ADRs End Mostly Lower; NIO Traded Actively
DJ
03/25VIR BIOTECHNOLOGY : US Food and Drug Administration Revises Emergency Use Authorization fo..
PU
03/25FDA says current dose of GSK-Vir COVID therapy unlikely to work against BA.2 variant
RE
03/25FDA Limits Use of Sotrovimab to Treat Covid-19 Due to BA.2 Omicron Subordinated-variant
DJ
03/25FDA Rules Smaller Doses of Vir, GlaxoSmithKline Monoclonical Antibody 'Unlikely' to be ..
MT
03/25VIR BIOTECHNOLOGY, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
03/25US Food and Drug Administration Revises Emergency Use Authorization for Sotrovimab Due ..
GL
03/25US Food and Drug Administration Revises Emergency Use Authorization for Sotrovimab Due ..
GL
03/24EU medicines regulator recommends AstraZeneca's drug for COVID prevention
RE
03/11COVID SCIENCE-GeoVax vaccine targeting virus in two places shows promise; virus may bec..
RE
03/04NORTH AMERICAN MORNING BRIEFING : Stock Futures -2-
DJ
03/03Baird Upgrades Vir Biotechnology to Neutral From Underperform, Adjusts Price Target to ..
MT
03/02WHO recommends Merck's COVID pill for high-risk patients
RE
03/02Vir Biotechnology to Participate in the 42nd Annual Cowen Healthcare Conference
AQ
02/28VIR BIOTECHNOLOGY, INC. Management's Discussion and Analysis of Financial Condition an..
AQ
02/25Vir Biotechnology Swings to Q4 Earnings as Revenue Climbs
MT
02/24VIR BIOTECHNOLOGY : Provides Corporate Update and Reports Fourth Quarter and Full Year 202..
PU
02/24VIR BIOTECHNOLOGY, INC. : Results of Operations and Financial Condition, Regulation FD Dis..
AQ
02/24Vir Biotechnology, Inc. Reports Earnings Results for the Fourth Quarter and Full Year E..
CI
02/24Earnings Flash (VIR) VIR BIOTECHNOLOGY Reports Q4 Revenue $812.7M, vs. Street Est of $6..
MT
02/24Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 20..
AQ
02/24US FDA Restricts Use of GlaxoSmithKline-Vir Biotechnology's COVID-19 Shot in Some Regio..
MT
02/24GlaxoSmithKline's Covid-19 Treatment Use Limited by FDA
DJ
02/23U.S. FDA limits use of GlaxoSmithKline-Vir COVID-19 drug
RE
1  2  3  4  5  6  7  8  9Next
Upcoming event on VIR BIOTECHNOLOGY, INC.